Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HC Wainwright

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Read Why HC Wainwright Cut Price Target For Dentsply Sirona

HC Wainwright has cut the price target for Dentsply Sirona Inc (NASDAQ:XRAY) from $58 to $48 (17% upside), reiterating the Neutral rating. The analysts have adjusted 2022 projections to reflect lower than expected Q1 FY22 earnings. Management noted that the results reflect weaker sales performance in the U.S., global supply chain challenges, and foreign exchange headwinds.…

Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why

TG Therapeutics Inc's (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) HC Wainwright has slashed the price target from $68 to $19, with the Buy rating unchanged.…

Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So

HC Wainwright has removed Angion Biomedica Corp's (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating. In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data. The analyst…

HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar

inkl

Read news from The Economist, FT, and more,
with one subscription

See Why Does HC Wainwright Maintain Neutral On Akebia Stock

See Why Does HC Wainwright Maintain Neutral On Akebia Stock

Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.

HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks

HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks

Atreca Inc (NASDAQ:BCEL) announced a licensing agreement with Zymeworks Inc (NYSE:ZYME) to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs). The agreement includes a two-year research term for Atreca to evaluate antibodies as ADCs using ZymeLink with the option for a third year. Atreca can acquire three commercial licenses to develop three unique…

HC Wainwright Sees Almost 1000% Upside On Spectrum Pharma Stock

HC Wainwright Sees Almost 1000% Upside On Spectrum Pharma Stock

HC Wainwright reiterates the Buy rating on Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a price target of $10. The analyst projects revenues of $170 million for Rolontis and $328 million for poziotinib in 2026. Eflapegrastim (formerly known as Rolontis; to be renamed) is a long-acting granulocyte colony-stimulating factor intended to stimulate neutrophil production for chemotherapy-induced neutropenia…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

GlaxoSmithKline Plc

Alnylam Pharmaceuticals Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

372,385 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play